Ernexa Therapeutics Inc. (ERNA) - 10-Q Summary
Business Context and Reporting Period
Company: Ernexa Therapeutics Inc.
Reporting Period: Quarter and six months ended June 30, 2026.
Business Model: Preclinical-stage synthetic allogeneic iMSC therapy company focused on cancer and autoimmune diseases. Lead candidate ERNA-101 targets platinum-resistant ovarian cancer; ERNA-201 targets autoimmune disorders.
Key Events: Effected a 1-for-25 reverse stock split in May 2026 to regain Nasdaq compliance. Completed a public offering in February 2026 raising approximately $9.5 million net. Filed a Universal Shelf registration statement in March 2026.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(9,515) | $(11,341) |
| Net Loss Attributable to Common Stockholders | $(9,523) | $(11,349) |
| Net Loss Per Share (Basic & Diluted) | $(9.63) | $(65.22) |
| Cash and Cash Equivalents (End of Period) | $5,028 | $4,315 |
| Operating Cash Flow | $(6,416) | $(4,597) |
| Financing Cash Flow | $9,565 | $7,183 |
| Total Assets | $6,315 | $5,834 |
| Total Liabilities | $3,115 | $3,433 |
| Stockholders' Equity | $3,200 | $2,401 |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased to $9.7 million for the six months ended June 30, 2026, from $5.2 million in the prior year period. This includes a one-time non-cash goodwill impairment charge of $2.0 million recognized in Q1 2026.
- Research & Development (R&D): R&D expenses rose to $4.7 million (from $2.4 million) driven by increased study fees for ERNA-101, higher payroll due to headcount growth, and manufacturing services fees.
- Non-Operating Items: The 2025 period included a $5.8 million expense related to a forward sales contract, which did not recur in 2026. In 2026, the company recognized a $41,000 gain from the extinguishment of a contingent consideration liability.
- Liquidity: Cash balance increased from $1.9 million at year-end 2025 to $5.0 million at June 30, 2026, primarily due to the February 2026 public offering.
Guidance, Outlook, and Risks
- Outlook: Management expects to complete IND-enabling studies and submit an Investigational New Drug (IND) application in 2026, with a Phase 1 clinical trial anticipated in the second half of 2026. Independent validation of ERNA-101 was announced in July 2026.
- Liquidity Risk: As of June 30, 2026, cash of $5.0 million is insufficient to fund operations for the next 12 months. The company relies on its At-the-Market (ATM) program (up to $9.2 million capacity) to cover shortfalls. Subsequent to the period end, the company raised an additional $3.7 million via the ATM.
- Nasdaq Compliance: The company regained compliance with the Nasdaq Bid Price Rule following the reverse stock split. However, it remains under a mandatory panel monitor until September 14, 2026, and must maintain compliance through May 5, 2027, to avoid delisting.
- Management Changes: The Senior Vice President of Finance resigned in June 2026. The CEO served as interim CFO until August 2026, when a fractional CFO was engaged.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.0 million cash balance plus remaining ATM capacity ($5.4 million) against the burn rate of ~$6.4 million per six months.
- Goodwill Impairment: Confirm the impact of the $2.0 million goodwill write-off on future balance sheet strength and the valuation of the 2018 acquisition.
- Capital Raise Execution: Monitor the utilization of the Universal Shelf and ATM program to ensure continued funding for the planned 2026 IND submission.
- Nasdaq Status: Track stock price performance to ensure continued compliance with the $1.00 minimum bid price requirement through the monitoring period.
- Related Party Transactions: Review the terms of the recent financing involving Charles Cherington (approx. 23% shareholder) and the repayment of related party promissory notes.